FSBP suppresses tumor cell migration by inhibiting the JNK pathway

Fangyu Song; Wenshuo Zhang; Xiaohui Li; Xiaoqing Chen; Xuejun Yuan; Mingjin Jiang; Yunhe Zhao; Qingxin Liu; Zizhang Zhou

doi:10.1016/j.isci.2023.106440

FSBP suppresses tumor cell migration by inhibiting the JNK pathway

iScience. 2023 Mar 17;26(4):106440. doi: 10.1016/j.isci.2023.106440. eCollection 2023 Apr 21.

Authors

Fangyu Song¹, Wenshuo Zhang^{1

2}, Xiaohui Li¹, Xiaoqing Chen¹, Xuejun Yuan¹, Mingjin Jiang³, Yunhe Zhao¹, Qingxin Liu¹, Zizhang Zhou¹

Affiliations

¹ College of Life Sciences, Shandong Agricultural University, Tai'an 271018, China.
² Fang Zongxi Center, MoE Key Laboratory of Marine Genetics and Breeding, College of Marine Life Sciences, Ocean University of China, Qingdao, China.
³ Jiangxi Provincial Institute of Translational Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Abstract

The main cause of high mortality in cancer patients is tumor metastasis. Exploring the underlying mechanism of tumor metastasis is of great significance for clinical treatments. Here, we identify the transcription factor Apt/FSBP is a suppressor for tumor metastasis. In Drosophila wing disc, knockdown of apt is able to trigger cell migration, whereas overexpression of apt hampers scrib-RNAi-induced tumor cell migration. Further studies show that loss of apt promotes cell migration through activating the JNK pathway. To investigate the role of FSBP, the homolog of Apt in mammals, we construct Fsbp liver-specific knockout mice. Knockout of Fsbp in liver does not cause any detectable physiological defects, but predisposes to tumorigenesis on DEN and CCl₄ treatment. In addition, loss of Fsbp accelerates tumor metastasis from liver to diaphragm. Taken together, this study uncovers FSBP is a novel tumor suppressor, and provides it as a considerable drug target for tumor treatment.

Keywords: Cancer; Cell biology; Cellular physiology.